Newsmeme!
Discover News you didn't know existed
Peripheral Stem Cell Transplantation
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
Pluristem Therapeutics Announces US$ 600,000 Restricted Share Purchase
Published December 3, 2008, 6:27 am, Business Wire via Yahoo! Finance
NEW YORK----Pluristem Therapeutics Inc. : Management and Board of Directors Invested Additional $150,000 in the Company
HemoGenix(R), Inc Announces Implementation of ORF Genetics Human Growth Factors and Cytokines in All Human HALO(R) ...
Published December 3, 2008, 5:30 am, PR Newswire via Yahoo! Finance
HemoGenix® and ORF Genetics announce the collaboration and implementation of biorisk-free, green-source growth factors and cytokines for use in all HALO® Assay Kits and HALO® Contract Research Services where the response of human blood-forming cells is detected.
Pluristem Therapeutics Announces US$ 600,000 Restricted Share Purchase
Published December 3, 2008, 3:17 am, Centre Daily Times
Pluristem Therapeutics Inc. (NasdaqCM: PSTI ) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of degenerative, ischemic and autoimmune indications, today announced it has entered into definitive agreements to sell common stock and warrants for aggregate gross proceeds of $600,000.
Pluristem Retains KKS as Its CRO for Upcoming Limb Ischemia Clinical Trial
Published December 1, 2008, 1:17 am, Centre Daily Times
Pluristem Therapeutics Inc. (NASDAQ:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of degenerative, ischemic and autoimmune indications, today announced that the Company signed an agreement with KKS, retaining them as the Contract Research Organization (CRO) for its upcoming Critical Limb ...
Pluristem Retains KKS as Its CRO for Upcoming Limb Ischemia Clinical Trial
Published December 1, 2008, 1:00 am, Business Wire via Yahoo! Finance
NEW YORK----Pluristem Therapeutics Inc. , a bio-therapeutics company dedicated to the commercialization of non-personalized cell therapy products for a variety of degenerative, ischemic and autoimmune indications, today announced that the Company signed an agreement with KKS, retaining them as the Contract Research Organization for its upcoming Critical Limb Ischemia multi center clinical trial ...
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |